Nonsurgical Closure of Esophago–Respiratory Fistulas: Role for the Somatostatin Analogue Octreotide Acetate?

Esophago-respiratory fistulas (ERF) do not close spontaneously and are uniformly fatal. A somatostatin analogue (octreotide acetate) was used in three consecutive patients to promote the closure of ERF. In 2 patients with esophageal cancer, treatment with octreotide acetate was associated with fistu...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of the medical sciences 1994-09, Vol.308 (3), p.152-156
Main Authors: Nylen, Eric S., Hall, James L., Krasnow, Steven H., Becker, Kenneth L., Wadleigh, Robert G.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biological and medical sciences
Digestive system
Esophageal cancer
Esophageal Fistula - drug therapy
Esophageal Fistula - etiology
Esophageal Neoplasms - complications
Esophago-respiratory fistula
Herpes Simplex - complications
Herpesvirus 1, Human
Humans
Male
Medical sciences
Middle Aged
Octreotide
Octreotide - therapeutic use
Pharmacology. Drug treatments
Respiratory System
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Esophago-respiratory fistulas (ERF) do not close spontaneously and are uniformly fatal. A somatostatin analogue (octreotide acetate) was used in three consecutive patients to promote the closure of ERF. In 2 patients with esophageal cancer, treatment with octreotide acetate was associated with fistula closure in 30 and 46days, respectively. In a third patient with virally-mdueed ERF, treatment was associated with improvement of the inflammation of the fistula before the patient’s death from pulmonary aspiration after 40days of treatment. These preliminary observations suggest that octreotide acetate treatment of ERF should receive further investigative scrutiny.
ISSN:0002-9629
1538-2990
DOI:10.1097/00000441-199409000-00005